Biomarin Pharmaceutical (BMRN) EBIT Growth (5y) (2014 - 2026)
Biomarin Pharmaceutical (BMRN) EBIT Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.89% |
| Dec 31, 2025 | 2.84% |
| Sep 30, 2025 | 3.55% |
| Jun 30, 2025 | 54.36% |
| Mar 31, 2025 | 16.36% |
| Dec 31, 2024 | 81.35% |
| Sep 30, 2024 | 95.29% |
| Jun 30, 2024 | 37.49% |
| Mar 31, 2024 | 29.48% |
| Dec 31, 2023 | 22.11% |
| Sep 30, 2023 | 31.55% |
| Jun 30, 2023 | 35.66% |
| Mar 31, 2023 | 27.78% |
| Dec 31, 2022 | -17.35% |
| Sep 30, 2022 | 29.35% |
| Jun 30, 2022 | 24.65% |
| Mar 31, 2022 | 54.47% |
| Dec 31, 2021 | 5.97% |
| Sep 30, 2021 | 2.40% |
| Jun 30, 2021 | 15.10% |